A 2026 BD opportunity scan of 1E Therapeutics, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of SynAct Pharma, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Vesper Bio ApS, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of TWi Biotechnology, Inc., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of TerSera Therapeutics LLC, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Reborna Biosciences, Inc., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of SCAI Therapeutics, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Orikine Bio SL, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of OnCusp Therapeutics Inc, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of ATB Therapeutics, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Onchilles Pharma, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Aliad Biopharma, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.